Teva, Intel to develop wearable technology for Huntington’s disease

[:it]Teva Pharmaceutical Industries Ltd (TEVA.TA) said on Thursday it was collaborating with Intel Corp (INTC.O) to develop a wearable technology platform to track the progression of disease in patients with Huntington’s, a fatal degenerative disorder.

The inherited condition causes the progressive breakdown of nerve cells in the brain, resulting in a gradual decline in motor control, cognition and mental stability.

There are no approved drugs to alter the course of Huntington’s, although there are medicines that help with symptoms. Patients typically succumb to the disease within 15‐25 years of diagnosis.

Teva (TEVA.N), with Intel, will deploy the technology as part of an ongoing mid-stage Huntington’s study, the Israeli company said on Thursday.

Patients will use a smartphone and wear a smartwatch equipped with sensing technology that will continuously measure functioning and movement.

The data from the devices will then be wirelessly streamed to a cloud-based platform, developed by Intel, that will translate it, in near real-time, into scores to assess motor symptom severity.

Fonte:http://mobile.reuters.com/article/idUSKCN11L1O0[:en]Teva Pharmaceutical Industries Ltd (TEVA.TA) said on Thursday it was collaborating with Intel Corp (INTC.O) to develop a wearable technology platform to track the progression of disease in patients with Huntington’s, a fatal degenerative disorder.

The inherited condition causes the progressive breakdown of nerve cells in the brain, resulting in a gradual decline in motor control, cognition and mental stability.

There are no approved drugs to alter the course of Huntington’s, although there are medicines that help with symptoms. Patients typically succumb to the disease within 15‐25 years of diagnosis.

Teva (TEVA.N), with Intel, will deploy the technology as part of an ongoing mid-stage Huntington’s study, the Israeli company said on Thursday.

Patients will use a smartphone and wear a smartwatch equipped with sensing technology that will continuously measure functioning and movement.

The data from the devices will then be wirelessly streamed to a cloud-based platform, developed by Intel, that will translate it, in near real-time, into scores to assess motor symptom severity.

Fonte:http://mobile.reuters.com/article/idUSKCN11L1O0[:]